MBX Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
MBX Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.25 |
| 52 Week High | US$27.50 |
| 52 Week Low | US$15.31 |
| Beta | 0 |
| 1 Month Change | -7.69% |
| 3 Month Change | -23.16% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -22.83% |
Recent News & Updates
Shareholder Returns
| MBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -16.6% | -1.9% | -2.8% |
| 1Y | n/a | 2.7% | 24.1% |
Return vs Industry: Insufficient data to determine how MBX performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MBX performed against the US Market.
Price Volatility
| MBX volatility | |
|---|---|
| MBX Average Weekly Movement | 11.9% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 18.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine MBX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 38 | Peter Hawryluk | mbxbio.com |
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery.
MBX Biosciences, Inc. Fundamentals Summary
| MBX fundamental statistics | |
|---|---|
| Market cap | US$615.88m |
| Earnings (TTM) | -US$55.18m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-11.1x
P/E RatioIs MBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$55.18m |
| Earnings | -US$55.18m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.65 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/02 04:57 |
| End of Day Share Price | 2025/01/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MBX Biosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Seamus Fernandez | Guggenheim Securities, LLC |
| Michael Yee | Jefferies LLC |
| Jessica Fye | J.P. Morgan |